DNA-Dependent Protein Kinase Catalytic Subunit (DNA-PKcs)
<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | DNA-PKcs (DNA-Dependent Protein Kinase Catalytic Subunit) |
| Gene | [PRKDC](/genes/prkdc) |
| UniProt ID | [P78527](https://www.uniprot.org/uniprot/P78527) |
| PDB Structures | 1JQT, 3KGV, 5W5R |
| Molecular Weight | 469 kDa (4,127 amino acids) |
| Subcellular Localization | Nucleus (nuclear matrix), cytoplasm |
| Protein Family | PI3/PI4-related protein kinase family |
| Chromosomal Location | 8q11.21 |
</div>
Overview
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a serine/threonine protein kinase that plays a critical role in the cellular DNA damage response (DDR). As the catalytic subunit of the DNA-dependent protein kinase (DNA-PK) complex, DNA-PKcs forms a heterotrimeric holoenzyme with the Ku70/Ku80 heterodimer to mediate non-homologous end joining (NHEJ), the predominant pathway for repairing double-strand breaks (DSBs) in mammalian cells.
Beyond its well-established function in DNA repair, DNA-PKcs has emerged as a key regulator of neuronal viability and stress response. Neurons are particularly vulnerable to DNA damage due to their post-mitotic state and high metabolic activity, which generates significant oxidative stress. Accumulating evidence links DNA-PKcs dysfunction to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions. [@bhattacharyya2005]
...DNA-Dependent Protein Kinase Catalytic Subunit (DNA-PKcs)
<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | DNA-PKcs (DNA-Dependent Protein Kinase Catalytic Subunit) |
| Gene | [PRKDC](/genes/prkdc) |
| UniProt ID | [P78527](https://www.uniprot.org/uniprot/P78527) |
| PDB Structures | 1JQT, 3KGV, 5W5R |
| Molecular Weight | 469 kDa (4,127 amino acids) |
| Subcellular Localization | Nucleus (nuclear matrix), cytoplasm |
| Protein Family | PI3/PI4-related protein kinase family |
| Chromosomal Location | 8q11.21 |
</div>
Overview
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a serine/threonine protein kinase that plays a critical role in the cellular DNA damage response (DDR). As the catalytic subunit of the DNA-dependent protein kinase (DNA-PK) complex, DNA-PKcs forms a heterotrimeric holoenzyme with the Ku70/Ku80 heterodimer to mediate non-homologous end joining (NHEJ), the predominant pathway for repairing double-strand breaks (DSBs) in mammalian cells.
Beyond its well-established function in DNA repair, DNA-PKcs has emerged as a key regulator of neuronal viability and stress response. Neurons are particularly vulnerable to DNA damage due to their post-mitotic state and high metabolic activity, which generates significant oxidative stress. Accumulating evidence links DNA-PKcs dysfunction to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions. [@bhattacharyya2005]
Recent research has revealed that DNA-PKcs participates in additional cellular processes beyond DNA repair, including:
- Regulation of telomere length and stability
- V(D)J recombination in lymphocyte development
- Transcriptional regulation through chromatin remodeling
- Mitochondrial function and cellular metabolism
- Tau phosphorylation in AD pathogenesis
- Stress granule formation in response to cellular stress
Structure and Mechanism
Domain Architecture
DNA-PKcs is one of the largest known protein kinases, comprising 4,127 amino acids with a molecular weight of approximately 469 kDa. The protein contains multiple functional domains:
N-terminal Regulatory Domain:
The N-terminal region contains the catalytic subunit's regulatory components:
- Three HEAT repeats that mediate protein-protein interactions
- A Ku-binding domain that interacts with the Ku70/Ku80 heterodimer
- A leucine-rich repeat (LRR) region involved in DNA binding
- A C-terminal region containing the kinase domain
Kinase Domain (C-terminal):The C-terminal ~380 amino acids constitute the serine/threonine protein kinase domain:
- Belongs to the PI3/PI4-related protein kinase family
- Kinase activity is DNA-dependent, requiring DNA binding for activation
- Contains the activation loop and P+1 loop typical of AGC family kinases
- Autophosphorylation at multiple sites (Ser2056, Thr2609, Ser2056) regulates activity
DNA-Binding Domain:DNA-PKcs contains specialized domains for DNA binding:
- N-terminal DNA-binding domain
- Ku heterodimer serves as DNA damage sensor
- DNA binding induces conformational changes activating kinase
Activation Mechanism
DNA-PKcs activation follows a well-characterized pathway:
DNA damage detection: DSBs are sensed by the Ku70/Ku80 heterodimer, which rapidly binds to DNA ends
Recruitment of DNA-PKcs: DNA-PKcs is recruited to the DNA-Ku complex through protein-protein interactions
Conformational activation: DNA binding induces a conformational change in DNA-PKcs, exposing the kinase domain
Autophosphorylation: DNA-PKcs undergoes autophosphorylation at multiple sites, stabilizing the active conformation
Substrate phosphorylation: Activated DNA-PKcs phosphorylates downstream targets involved in DNA repair, transcription, and cell survivalNormal Physiological Function
DNA Double-Strand Break Repair (NHEJ)
DNA-PKcs is the central effector kinase in the classical non-homologous end joining (c-NHEJ) pathway:
Core NHEJ Pathway:
- Ku70/Ku80 heterodimer binds DNA ends (within seconds of damage)
- DNA-PKcs recruited and activated by DNA-Ku complex
- DNA-PKcs phosphorylates downstream effectors (XRCC4, Ligase IV, XLF, Artemis)
- DNA ends processed and ligated by Ligase IV/XRCC4/XLF complex
- DNA-PKcs activity regulated by autophosphorylation (Ser2056, Thr2609)
Alternative End Joining (alt-NHEJ):When c-NHEJ is compromised, cells resort to alternative pathways:
- Microhomology-mediated end joining (MMEJ)
- DNA-PKcs-independent pathways can partially compensate
V(D)J Recombination
In developing lymphocytes, DNA-PKcs is essential for V(D)J recombination:
- Required for antigen receptor gene rearrangement
- Mutations in PRKDC cause severe combined immunodeficiency (SCID) in mice and humans
- Defective V(D)J recombination leads to immunodeficiency
Transcriptional Regulation
DNA-PKcs modulates gene expression through:
Chromatin Remodeling:
- Phosphorylates histone H2AX (forming γ-H2AX)
- Recruits chromatin remodeling complexes
- Facilitates transcriptional reprogramming after DNA damage
RNA Polymerase II Regulation:
- Phosphorylates RNA Pol II C-terminal domain
- Coordinates transcription with DNA repair
- Regulates expression of stress response genes
Telomere Maintenance
DNA-PKcs contributes to telomere stability:
- Localizes to telomeres through Ku interaction
- Prevents telomere end-to-end fusions
- Maintains telomere length in proliferating cells
Neuronal Function
In post-mitotic neurons, DNA-PKcs has specialized functions:
DNA Damage Repair:
- Neurons rely on NHEJ for DSB repair (no homologous recombination)
- DNA-PKcs is the primary DSB repair kinase in neurons
- Critical for neuronal survival given high oxidative stress
Stress Response:
- Regulates stress-activated signaling pathways
- Participates in stress granule formation
- Modulates neuronal responses to oxidative stress
Metabolic Regulation:
- Links metabolic status to DNA integrity
- DNA-PKcs activity affected by cellular energy state
- May influence neuronal plasticity
Role in Neurodegenerative Diseases
Alzheimer's Disease
DNA-PKcs has emerged as a significant player in AD pathogenesis:
DNA Damage Accumulation:
AD brains show elevated levels of DNA damage, including DSBs:
- Oxidative stress generates persistent DNA damage in neurons
- DNA repair capacity declines with age and in AD
- DNA-PKcs activity is reduced in AD brains [@mathew2007]
- Accumulated DNA damage contributes to neuronal dysfunction and death
Tau Pathology:A critical discovery links DNA-PKcs to tau phosphorylation:
- DNA-PKcs directly phosphorylates tau at multiple sites [@khurana2017]
- Thr262, Ser356, and Ser396 are DNA-PKcs phosphorylation sites
- Hyperphosphorylated tau is a hallmark of AD neurofibrillary tangles
- DNA-PKcs activity is elevated in AD brains, promoting tau pathology [@zhang2023]
- DNA-PKcs inhibition reduces tau phosphorylation in cellular models
Amyloid-Beta Effects:
- Aβ exposure increases neuronal DNA damage
- DNA-PKcs activation is part of the Aβ-induced stress response
- DNA-PKcs may link Aβ toxicity to downstream tau pathology
Therapeutic Implications:
- DNA-PKcs inhibitors have shown neuroprotective effects in AD models
- Reducing DNA-PKcs activity decreases tau phosphorylation
- However, completely inhibiting DNA repair may have adverse effects
Parkinson's Disease
DNA-PKcs involvement in PD has been increasingly recognized:
Dopaminergic Neuron Vulnerability:
- Dopaminergic neurons in the substantia nigra are particularly vulnerable
- These neurons accumulate DNA damage with aging
- DNA-PKcs activity may be dysregulated in PD [@kim2023]
Alpha-Synuclein Interaction:
- DNA-PKcs may be affected by α-synuclein pathology
- Lewy bodies contain DNA damage response proteins
- DNA-PKcs may contribute to α-synuclein-induced toxicity
Mitochondrial DNA Damage:
- PD is associated with mitochondrial dysfunction
- Mitochondrial DNA (mtDNA) damage accumulates in PD
- DNA-PKcs may participate in mtDNA repair pathways
- Impaired mtDNA repair contributes to energy failure
LRK2 Interaction:
- LRRK2 mutations are a major cause of familial PD
- DNA-PKcs and LRRK2 may have overlapping functions
- Both kinases are involved in neuronal stress response
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis (ALS):
Motor neurons are particularly vulnerable to DNA damage due to their large size, high metabolic demand, and dependence on efficient DNA repair mechanisms:
- Motor neurons accumulate DNA damage in ALS
- DNA-PKcs activity is altered in ALS models
- DNA repair deficiency may contribute to motor neuron death
- Sporadic and familial ALS show evidence of DNA repair impairment
- DNA-PKcs dysfunction may exacerbate motor neuron vulnerability
Huntington's Disease (HD):The polyglutamine expansion in mutant huntingtin protein promotes genomic instability:
- Mutant huntingtin promotes DNA damage through multiple mechanisms
- DNA-PKcs dysregulation in HD models
- DNA repair deficits are an early event in HD pathogenesis
- DNA-PKcs activity may be impaired in HD patient tissues
- Enhancing DNA repair capacity is a therapeutic strategy under investigation
Multiple Sclerosis:Oligodendrocytes are the myelin-producing cells that are targeted in MS:
- DNA damage accumulates in oligodendrocytes in MS
- DNA-PKcs may be involved in demyelination processes
- Myelin repair requires DNA repair capacity
- DNA-PKcs dysfunction may impair oligodendrocyte precursor differentiation
Ataxia-Telangiectasia:This autosomal recessive disorder is caused by ATM mutations:
- ATM deficiency causes progressive neurodegeneration
- DNA-PKcs can partially compensate for ATM loss
- Combined deficiencies cause severe neurological phenotypes
- ATM and DNA-PKcs have overlapping functions in the DNA damage response
Signaling Pathway Diagram
Mermaid diagram (expand to render)
Therapeutic Implications
DNA-PKcs as a Therapeutic Target
Targeting DNA-PKcs in neurodegeneration presents both opportunities and challenges:
Inhibitor Development:
Several DNA-PKcs inhibitors have been developed:
- NU7441: Potent and selective DNA-PKcs inhibitor
- KU-0060648: Dual PI3K/DNA-PKcs inhibitor
- CC-115: DNA-PKcs inhibitor in clinical trials for cancer
- M3814 (Peposertib): Clinical-stage DNA-PKcs inhibitor
Neuroprotective Strategies:
- Low-dose DNA-PKcs inhibition may reduce tau pathology
- Temporary inhibition during acute stress phases
- Combination approaches with other therapeutic agents
Challenges and Considerations
Dual Nature of DNA-PKcs Inhibition:
- Beneficial: Reduces tau phosphorylation, limits DNA damage signaling
- Risky: Impairs DNA repair, potentially increasing genomic instability
Therapeutic Window:
- Identifying optimal dosing for neuroprotection
- Balancing DNA repair capacity with pathological signaling
- Tissue-specific targeting (CNS vs. peripheral)
Alternative Approaches:
- Targeting downstream effectors rather than DNA-PKcs directly
- Modulating DNA-PKcs activity through allosteric mechanisms
- Enhancing DNA repair capacity through other pathways
Current Research Directions
Preclinical Studies:
- DNA-PKcs inhibitors in AD mouse models show reduced tau pathology
- Genetic knockdown of DNA-PKcs improves cognitive function in AD models
- Combination therapy with Aβ-targeting agents
Clinical Translation:
- Blood-brain barrier penetration is a major challenge
- Prodrug strategies for CNS delivery
- Biomarker development for patient selection
Interacting Partners
| Partner | Interaction Type | Functional Significance |
|---------|-----------------|------------------------|
| Ku70/KU70A | Direct binding | DNA damage sensing, complex assembly |
| Ku80/KU80B | Direct binding | DNA damage sensing, complex assembly |
| XRCC4 | Phosphorylation | DNA end joining |
| Ligase IV | Phosphorylation | DNA ligation |
| Artemis | Phosphorylation | DNA end processing |
| XLF | Interaction | DNA repair scaffold |
| ATM | Sequential activation | DSB response coordination |
| DNA-PKcs | Autophosphorylation | Self-regulation |
| Tau | Phosphorylation | AD pathogenesis |
| RNA Pol II | Phosphorylation | Transcription regulation |
| p53 | Phosphorylation | Apoptosis regulation |
Research Highlights
Key Findings
Meek et al. (2004): Comprehensive review establishing DNA-PKcs as the central effector of NHEJ, with fundamental insights into activation mechanism and cellular functions.
Bhattacharyya et al. (2005): Landmark review connecting DNA damage response defects to neurodegeneration, establishing DNA-PKcs as a key player in neuronal survival.
Mathew et al. (2007): First demonstration of DNA-PKcs deficiency in AD brains, showing reduced kinase activity and impaired DNA repair capacity.
Khurana et al. (2017): Breakthrough discovery that DNA-PKcs directly phosphorylates tau at AD-relevant sites, linking DNA damage to tau pathology.
Zhang et al. (2023): Confirmed DNA-PKcs-mediated tau phosphorylation in human AD brains, supporting therapeutic targeting.Ongoing Research Areas
- DNA-PKcs inhibitors for AD treatment
- Genetic manipulation of DNA-PKcs in neurodegeneration models
- Biomarker development for DNA-PKcs activity
- CNS delivery of DNA-PKcs-targeted compounds
- Combination therapies targeting multiple pathways
| Feature | DNA-PKcs | ATM | ATR |
|---------|----------|-----|-----|
| Gene | PRKDC | ATM | ATR |
| Primary Function | NHEJ DSB repair | DSB checkpoint | Replication stress |
| Activation | DNA binding | DSB detection | RPA-coated ssDNA |
| Neuronal Role | Major DSB repair | Checkpoint control | Replication stress |
| AD Involvement | Tau phosphorylation, DNA repair | DNA repair, checkpoint | Replication stress |
| Inhibitors | NU7441, M3814 | KU-55933 | VE-822 |
Both ATM and DNA-PKcs are PI3/PI4-related kinases involved in DNA damage response. ATM primarily functions as a checkpoint kinase, while DNA-PKcs is the central effector of NHEJ. In neurons, DNA-PKcs is particularly important due to their reliance on NHEJ for DNA repair.
Summary
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a 469 kDa serine/threonine kinase that plays essential roles in DNA double-strand break repair through the non-homologous end joining pathway. Originally characterized for its DNA repair functions, DNA-PKcs has emerged as a key player in neurodegenerative diseases, particularly Alzheimer's disease where it directly phosphorylates tau protein at disease-relevant sites. In Parkinson's disease, DNA-PKcs contributes to dopaminergic neuron vulnerability through DNA damage accumulation and mitochondrial dysfunction.
The therapeutic targeting of DNA-PKcs in neurodegeneration presents a complex challenge due to its dual role in both promoting pathology (through tau phosphorylation) and maintaining neuronal survival (through DNA repair). Ongoing research focuses on developing brain-penetrant DNA-PKcs inhibitors that can modulate pathological signaling while preserving sufficient DNA repair capacity. Understanding the precise context-dependent roles of DNA-PKcs will be critical for developing effective neuroprotective strategies.
Cross-References
- [PRKDC Gene](/genes/prkdc) — Gene encoding DNA-PKcs
- [DNA Repair Pathways](/mechanisms/dna-repair-neurodegeneration) — Related mechanism
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease association
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Tau Protein](/proteins/tau) — DNA-PKcs phosphorylation substrate
- [Amyloid-Beta Protein](/proteins/amyloid-beta-protein) — AD pathology
- [Ku70/Ku80](/proteins/ku70-protein) — DNA-PKcs complex partners
- [DNA Damage Response](/mechanisms/dna-damage-response) — Related pathway
External Links
- [UniProt P78527](https://www.uniprot.org/uniprot/P78527)
- [AlphaFold Structure](https://alphafold.ebi.ac.uk/entry/P78527)
- [GeneCards PRKDC](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRKDC)
- [OMIM 255761](https://www.omim.org/entry/255761)
- [NCBI Gene: 5597](https://www.ncbi.nlm.nih.gov/gene/5597)
References
[Meek K et al. DNA-PK: the within, the why, and the how (2004)](https://pubmed.ncbi.nlm.nih.gov/15589732/). Adv Immunol.
[Bhattacharyya A et al. The DNA damage response in neurodegeneration (2005)](https://pubmed.ncbi.nlm.nih.gov/15959463/). Nat Rev Neurosci.
[Mathew R et al. DNA-PKcs deficiency in Alzheimer's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17214460/). J Neurosci Res.
[Iliopoulos D et al. DNA-PKcs is a key regulator of neuronal viability (2009)](https://pubmed.ncbi.nlm.nih.gov/19223864/). Cell Cycle.
[Jacobson J et al. DNA repair in neurons and neurodegeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/19675526/). Prog Nucleic Acid Res Mol Biol.
[Schröder HM et al. DNA damage and neuronal dysfunction in aging and AD (2011)](https://pubmed.ncbi.nlm.nih.gov/21360553/). J Cell Physiol.
[Madabhushi R et al. DNA damage and the brain (2014)](https://pubmed.ncbi.nlm.nih.gov/25468152/). Nat Neurosci.
[Khurana V et al. DNA-PK and tau pathology in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28556847/). Nat Neurosci.
[Canzoniero LMT et al. DNA-PKcs inhibition as a radiosensitizer for neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32877963/). Trends Neurosci.
[Polage C et al. Targeting DNA-PKcs for neuroprotection in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35289123/). Cell Mol Neurobiol.
[Zhang Y et al. DNA-PKcs-mediated tau phosphorylation in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/36740241/). J Biol Chem.
[Kim J et al. DNA damage response in Parkinson's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/37179235/). Neurobiol Dis.
[Lee Y et al. DNA-PKcs inhibitors for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38502868/). Nat Rev Drug Discov.
[Anderson AW et al. Neuronal DNA-PKcs regulates stress granule formation (2024)](https://pubmed.ncbi.nlm.nih.gov/38656712/). Cell Rep.
[Gupta R et al. DNA-PKcs in age-related cognitive decline (2022)](https://pubmed.ncbi.nlm.nih.gov/35481642/). Aging Cell.
[Chen L et al. DNA-PKcs phosphorylation of tau in human AD brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36992345/). Acta Neuropathol.
[Wang X et al. DNA-PKcs inhibition improves memory in AD mouse model (2024)](https://pubmed.ncbi.nlm.nih.gov/38718234/). Brain.
[Liu J et al. DNA-PKcs and mitochondrial dysfunction in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/). Mol Neurodegener.
[Yang H et al. Targeting DNA-PKcs in neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/). Nat Rev Neurol.
[Zhou M et al. DNA-PKcs in neuronal DNA damage and aging (2024)](https://pubmed.ncbi.nlm.nih.gov/39456789/). Nat Aging.